PROACTIF - BTG 007996-01 (Phase IV / Registre)

Investigator physician: Dr Elodie CHEVALIER

A prospective, post-authorization, multicenter, open-label, non-interventional registry study to evaluate the efficacy of TheraSphere® in clinical practice in France

Unresectable hepatocellular carcinoma (HCC)

Prospective, non-interventional, single-arm, open-label, post-enrollment, multicenter study conducted in a single territory, France, for patients treated with TheraSphere with prescription and reimbursement.
Patients who agree to participate are given quality-of-life questionnaires for the study.

Treatment: TheraSphere, Yttrium-90 glass microspheres (routine care)
Study status: Recruiting
Clinical Trial number:
Funding: